Product References — Human Plasma

A Systematic Study of the In Vitro Pharmacokinetics and Estimated Human In Vivo Clearance of Indole and Indazole-3-Carboxamide Synthetic Cannabinoid Receptor Agonists Detected on the Illicit Drug Market

Posted by Adam Awdish on

A Systematic Study of the In Vitro Pharmacokinetics and Estimated Human In Vivo Clearance of Indole and Indazole-3-Carboxamide Synthetic Cannabinoid Receptor Agonists Detected on the Illicit Drug Market

Pooled Human Plasma Apheresis Derived from Innovative Research was used in the following study:   A Systematic Study of the In Vitro Pharmacokinetics and Estimated Human In Vivo Clearance of Indole and Indazole-3-Carboxamide Synthetic Cannabinoid Receptor Agonists Detected on the Illicit Drug Market Andrew M. Brandon, Lysbeth H. Antonides, Jennifer Riley, Ola Epemolu, Denise A. McKeown, Kevin D. Read, and Craig McKenzie Molecules March 5, 2021 A new, diverse group of synthetic drugs designed to activate human cannabinoid receptors CB1 and CB2 have emerged in the illicit drug market over recent years. These synthetic cannabinoid receptor agonists (SCRAs) have been...

Read more →

Can Remdesivir and its Parent Nucleoside GS-441524 be Potential Oral Drugs? An in vitro and in vivo DMPK Assessment

Posted by Adam Awdish on

Can Remdesivir and its Parent Nucleoside GS-441524 be Potential Oral Drugs? An in vitro and in vivo DMPK Assessment

Innovative Grade US Origin Mouse CD1 Plasma and Pooled Human Plasma Apheresis Derived from Innovative Research were used in the following study:   Can Remdesivir and its Parent Nucleoside GS-441524 be Potential Oral Drugs? An in vitro and in vivo DMPK Assessment Jiashu Xie, Zhengqiang Wang Acta Pharmaceutica Sinica B March 5, 2021 To date, the only FDA-approved drug for treating COVID-19 is Remdesivir (RDV), which can only be administered intravenously. RDV is a ProTide drug derived from nucleoside GS-441524, and the potency of RDV is dependent on intracellular conversion into GS-441524 triphosphate. In vitro studies of RDV in human...

Read more →

α-Synuclein in Blood Exosomes Immunoprecipitated Using Neuronal and Oligodendroglial Markers Distinguishes Parkinson’s Disease from Multiple System Atrophy

Posted by Adam Awdish on

α-Synuclein in Blood Exosomes Immunoprecipitated Using Neuronal and Oligodendroglial Markers Distinguishes Parkinson’s Disease from Multiple System Atrophy

Pooled Human Plasma (Blood Derived) and Pooled Human Serum Off the Clot from Innovative Research were used in the following study:   α-Synuclein in Blood Exosomes Immunoprecipitated Using Neuronal and Oligodendroglial Markers Distinguishes Parkinson’s Disease from Multiple System Atrophy Suman Dutta, Simon Hornung, Adira Kruayatidee, Katherine N. Maina, Irish del Rosario, Kimberly C. Paul, Darice Y. Wong, Aline Duarte Folle, Daniela Markovic, Jose-Alberto Palma, Geidy E. Serrano, Charles H. Adler, Susan L. Perlman, Wayne W. Poon, Un Jung Kang, Roy N. Alcalay, Miriam Sklerov, Karen H. Gylys, Horacio Kaufmann, Brent L. Fogel, Jeff M. Bronstein, Beate Ritz & Gal Bitan...

Read more →

A Universal Anti-Xa Assay for Rivaroxaban, Apixaban, and Edoxaban Measurements: Method Validation, Diagnostic Accuracy and External Validation

Posted by Adam Awdish on

A Universal Anti-Xa Assay for Rivaroxaban, Apixaban, and Edoxaban Measurements: Method Validation, Diagnostic Accuracy and External Validation

Pooled Human Plasma (Blood Derived) from Innovative Research was used in the following study:   A Universal Anti-Xa Assay for Rivaroxaban, Apixaban, and Edoxaban Measurements: Method Validation, Diagnostic Accuracy and External Validation Guido Willekens, Jan-Dirk Studt, Adriana Mendez, Lorenzo Alberio, Pierre Fontana, Walter A. Wuillemin, Adrian Schmidt, Lukas Graf, Bernhard Gerber, Cedric Bovet, Thomas C. Sauter, and Michael Nagler British Journal of Haematology March 19, 2021 When it comes to medical treatments and emergency care, any treatment involving anticoagulants naturally carries the risk of increased bleeding. In fact, uncontrolled bleeding is the leading cause of death in trauma patients. Knowing...

Read more →

Soluble Sema4D in Plasma of Head and Neck Squamous Cell Carcinoma Patients is Associated with Underlying Non-Inflamed Tumor Profile

Posted by Adam Awdish on

Soluble Sema4D in Plasma of Head and Neck Squamous Cell Carcinoma Patients is Associated with Underlying Non-Inflamed Tumor Profile

Single Donor Human Plasma (Blood Derived) from Innovative Research was used in the following study:   Soluble Sema4D in Plasma of Head and Neck Squamous Cell Carcinoma Patients is Associated with Underlying Non-Inflamed Tumor Profile Rania H. Younis, Ioana Ghita, Manar Elnaggar, Risa Chaisuparat, Vasileios Ionas Theofilou, Donita Dyalram, Robert A. Ord, Eduardo Davila, Luke J. Tallon, John C. Papadimitriou, Tonya J. Webb, Søren M. Bentzen, and Joshua E. Lubek Frontiers in Immunology March 11, 2021 Semaphorin 4D (Sema4D) is a glycoprotein that is capable of functioning as both a membrane bound protein or as a cleaved soluble protein (sSema4D),...

Read more →


×